Trial Profile
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Corticosteroid-induced osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 09 Jan 2024 Status changed from active, no longer recruiting to completed.
- 23 Sep 2021 Planned End Date changed from 22 May 2029 to 13 Dec 2023.
- 23 Sep 2021 Planned primary completion date changed from 26 May 2026 to 13 Dec 2023.